Non-invasive cell-tracking methods for adoptive T cell therapies.

Area of Science:

• Immunology
• Biomedical Engineering
• Oncology

Background:

• Adoptive T cell therapies (ACT) have achieved success in hematologic malignancies and melanoma.
• Significant challenges remain, including high costs, severe adverse events, and limited efficacy in solid tumors.

Purpose of the Study:

• To review the principles and potential of in vivo cell-tracking for adoptive T cell therapies.
• To discuss clinically relevant labeling strategies and their application in ACT.

Main Methods:

• Review of existing literature on in vivo cell-tracking techniques.
• Analysis of labeling strategies for T cells used in adoptive cell therapy.
• Discussion of the clinical implications of cell-tracking in patient management.

Main Results:

• In vivo cell-tracking enables real-time, non-invasive monitoring of T cell distribution, tumor homing, persistence, and organ redistribution.
• Cell-tracking can facilitate early detection of non-responders and adverse events.
• Various labeling strategies exist with potential clinical relevance for ACT.

Conclusions:

• In vivo cell-tracking is a valuable tool for monitoring and managing patients undergoing ACT.
• Addressing challenges in cell-tracking and labeling is crucial for expanding ACT applicability, especially in solid tumors.
• Further development and clinical integration of cell-tracking technologies can enhance the safety and efficacy of ACT.